What is the clinical evidence from this study?

Study design: Cross-Sectional. Population: Aortic valve sclerosis (n=168). Intervention: Aortic valve sclerosis (AVSc) vs. Normal aortic valve (NAV). Primary outcome: Log (MMP-9/TIMP-1) ratio (β 0.78, 95% CI 0.52-1.04, p=<0.001).

May 13, 2026Open Access

Matrix metalloproteinase activation and TNF upregulation characterize the sclerotic phase of aortic valve disease

Q: What are the key findings of this study?

Aortic valve sclerosis was independently associated with a higher MMP-9/TIMP-1 ratio (β 0.78) compared to normal aortic valves, indicating an active proteolytic and inflammatory profile.

Key Result

Aortic valve sclerosis was independently associated with a higher MMP-9/TIMP-1 ratio (β 0.78) compared to normal aortic valves, indicating an active proteolytic and inflammatory profile.

Study Design

Type

Cross-Sectional (n=168)

Multicenter

Structured PICO

Population

168 participants including 29 with normal aortic valve (NAV), 98 with aortic valve sclerosis (AVSc), and 41 with aortic stenosis (AS)

Outcome

Serum levels of matrix metalloproteinase (MMP)-1, -2, -3, and -9, tissue inhibitor of metalloproteinases-1 (TIMP-1), tumor necrosis factor (TNF), interleukin-6 (IL-6), and transforming growth factor-beta (TGF-β)surrogate

Aortic valve sclerosis is characterized by an active proteolytic and inflammatory biomarker profile, specifically elevated MMP-9 and TNF with reduced TIMP-1, distinguishing it from normal valves and aortic stenosis.

Main Result

Effect estimate: β 0.78 (95% CI 0.52-1.04)

Absolute Event Rate: 11% vs 4.8%

p-value: p=<0.001

Limitations

Cross-sectional design precludes causal inference or assessment of progression from sclerosis to stenosis.
Patients with AS were older and had more comorbidities, complicating direct comparisons.
Quantified circulating biomarkers may not fully represent local valvular processes.

Abstract

Introduction Aortic valve sclerosis (AVSc) is an active pathological process driven by extracellular matrix remodeling, consistent with a potentially reversible early stage of aortic valve disease. Methods In this cross-sectional study of 168 participants (29, normal aortic valve NAV; 98, AVSc; 41, aortic stenosis AS), serum levels of matrix metalloproteinase (MMP)-1, -2, -3, and -9, tissue inhibitor of metalloproteinases-1 (TIMP-1), tumor necrosis factor (TNF), interleukin-6 (IL-6), and transforming growth factor-beta (TGF-β) were measured. Multivariable adjustments were performed. Results Compared with AS, AVSc was associated with higher circulating MMP-9 levels, with MMP-9 also increased relative to NAV. TIMP-1 concentrations were reduced in AVSc compared with both AS and NAV. TNF levels were higher in AVSc than in AS, while IL-6 and TGF-β did not differ among groups. Notably, MMP-9/TIMP-1 ratio was markedly increased in AVSc. Discussion Our findings suggest that AVSc may exhibit an active proteolytic and inflammatory profile amenable to targeted anti-inflammatory and anti-proteolytic interventions.

AIに質問

Bookmark

View Full Paper